2023 was a good year for drug discovery. Mullard et al. (2024) report:
The FDA’s Center for Drug Evaluation and Research (CDER) approved 55 new drugs in 2023, as the pharmacopeia of small molecules and biologics continues to grow. This cohort is almost 50% larger than the new approval class of 2022, which fell below the approval trend line. CDER’s 10-year rolling average of new approvals is now 46 per year, the highest in more than 20 years. The low point was 2010, when this average bottomed out at 25 per year.
The full list of approvals can be found here.
